SPTX
Seaport Therapeutics, Inc.Marquee-fund ownership over time
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Pershing Square | Q4 2024 | Q1 2025 | — | +0% |
| Citadel Advisors | Q4 2024 | Q1 2025 | — | +0% |
| Millennium Management | Q4 2024 | Q1 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Seaport Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 6, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-209701May 6, 2026
- Form 40001193125-26-204507May 4, 2026
- Form 40001193125-26-204494May 4, 2026
- Form 40001193125-26-204493May 4, 2026
- Form 40001193125-26-204484May 4, 2026
- Form 40001193125-26-204483May 4, 2026
- Form 40001193125-26-204479May 4, 2026
- Form 40001193125-26-204471May 4, 2026
- Form 40001193125-26-204468May 4, 2026
- Form 40001193125-26-204465May 4, 2026
- Form 40001193125-26-204458May 4, 2026
- Form 40001193125-26-204456May 4, 2026
- Form 40001193125-26-204452May 4, 2026
- Form 40001193125-26-204449May 4, 2026
Fundamentals
XBRL · Seaport Therapeutics, Inc.Not enough XBRL history to plot. Seaport Therapeutics, Inc.hasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Seaport Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Pershing Square | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
| Millennium Management | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.